Table 3.
Coverage of regional nodes based on RTOG, ESTRO, RADCOMP and RUIJIN guidelines
|
Total population
( n = 154) |
RTOG guideline
n (%) |
ESTRO guideline
n (%) |
RADCOMP guideline
n (%) |
RUIJIN guideline
n (%) |
| Total | 205/348 (58.9%) a1 | 202/348 (58.0%) a1 | 306/348 (87.9%) b1 | 291/348 (83.6%) b1 |
| ALN-I | 75/109 (68.8%) a2 | 65/109 (59.6%) a2 | 75/109 (68.8%) a2 | 75/109 (68.8%) a2 |
| ALN-II | 14/46 (30.4%) a3 | 42/46 (91.30%) b3 | 46/46 (100.0%) b3 | 42/46 (91.3%) b3 |
| ALN-III | 32/36 (88.9%) a4,b4 | 27/36 (75.0%) b4 | 35/36 (97.2%) a4 | 32/36 (88.9%) a4,b4 |
| RN | 17/17 (100.0%) a5 | 17/17 (100.0%) a5 | 17/17 (100.0%) a5 | 17/17 (100.0%) a5 |
| SC-M | 59/68 (86.8%) a6 | 23/68 (33.8%) b6 | 66/68 (97.1%) a6 | 64/68 (94.1%) a6 |
| SC-L | 0/36 (0.0%) a7 | 0/36 (0.0%) a7 | 34/36 (94.4%) b7 | 30/36 (83.3%) b7 |
| IMN | 8/36 (22.2%) a8 | 28/36 (77.8%) b8 | 33/36 (91.7%) b8 | 31/36 (86.1%) b8 |
|
Primary non-metastatic
( n = 55) |
RTOG guideline
n (%) |
ESTRO guideline
n (%) |
RADCOMP guideline
n (%) |
RUIJIN guideline
n (%) |
| Total | 31/61 (50.8%) a9 | 45/61 (73.8%) a9,b9 | 60/61 (98.4%) c9 | 55/61 (90.2%) b9,c9 |
| ALN-I | Not evaluated | |||
| ALN-II | 1/15 (6.7%) a10 | 14/15 (93.3%) b10 | 15/15 (100%) b10 | 14/15 (93.3%) b10 |
| ALN-III | 9/10 (90.0%) a11 | 8/10 (80.0%) a11 | 10/10 (100%) a11 | 9/10 (90.0%) a11 |
| RN | 7/7 (100%) a12 | 7/7 (100%) a12 | 7/7 (100%) a12 | 7/7 (100.0%) a12 |
| SC-M | 11/12 (91.7%) a13 | 8/12 (66.7%) a13 | 11/12 (91.7%) a13 | 11/12 (91.7%) a13 |
| SC-L | 0/7 (0%) a14 | 0/7 (0%) a14 | 7/7 (100%) b14 | 5/7 (71.4%) b14 |
| IMN | 3/10 (30.0%) a15 | 8/10 (80.0%) a15,b15 | 10/10 (100%) b15 | 9/10 (90.0%) b15 |
|
Recurrent (with/without RNI)
( n = 50) |
RTOG guideline
n (%) |
ESTRO guideline
n (%) |
RADCOMP guideline
n (%) |
RUIJIN guideline
n (%) |
| Total | 51/94 (54.3%) a16 | 44/94 (46.8%) a16 | 86/94 (91.5%) b16 | 83/94 (88.3%) b16 |
| ALN-I | 6/8 (75.0%) a17 | 5/8 (62.5%) a17 | 6/8 (75.0%) a17 | 6/8 (75.0%) a17 |
| ALN-II | 6/8 (75.0%) a18 | 7/8 (87.5%) a18 | 8/8 (100%) a18 | 7/8 (87.5%) a18 |
| ALN-III | 5/6 (83.3%) a19 | 4/6 (66.7%) a19 | 5/6 (83.3%) a19 | 5/6 (83.3%) a19 |
| RN | 4/4 (100%) a20 | 4/4 (100%) a20 | 4/4 (100%) a20 | 4/4 (100%) a20 |
| SC-M | 25/31 (80.6%) a21 | 9/31 (29.0%) b21 | 30/31 (96.8%) a21 | 29/31 (93.5%) a21 |
| SC-L | 0/17 (0%) a22 | 0/17 (0%) a22 | 15/17 (88.2%) b22 | 15/17 (88.2%) b22 |
| IMN | 4/19 (21.1%) a23 | 14/19 (73.7%) b23 | 17/19 (89.5%) b23 | 16/19 (84.2%) b23 |
ALN-I, axillary lymph node level I; ALN-II, axillary lymph node level II; ALN-III, axillary lymph node level III; ESTRO, European Society for Radiation Therapy and Oncology; IMN, internal mammary nodes; RADCOMP, Radiotherapy Comparative Effectiveness; RN, Rotter’s nodes; RTOG, Radiation Therapy Oncology Group; SC-L, lateral supraclavicular; SC-M, medial supraclavicular.